Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant

Amelia Altavilla, Roberto Iacovelli, Giuseppe Procopio, Daniele Alesini, Emanuela Risi, Giuseppe Maria Campennì, Antonella Palazzo, Enrico Cortesi

Research output: Contribution to journalArticlepeer-review


The current landscape of treatment of castration-resistant prostate cancer (CRPC) has recently changed. Cabazitaxel, a new taxane with potential antineoplastic activity, has been approved by Food and Drug Administration (FDA) after docetaxel failure. In a phase III trial, cabazitaxel showed increased overall survival (OS) compared with mitoxantrone (15.1 vs. 12.7 mo, HR 0.70, 95% CI 0.59-0.83, p <0.0001). Furthermore, chemotherapy is not the only strategy available: several studies have shown as CRPC remains dependent on androgen receptor function for growth. Abiraterone acetate, an irreversible inhibitor of CYP17, has also been approved by the FDA after docetaxel failure. In a phase III trial comparing abiraterone acetate to placebo, abiraterone showed improvement in OS (14.8 vs. 10.4 mo, HR 0.65, 95% CI 0.54-0.77; p <0.0001). This review will discuss current options and the ongoing trials for second-line treatment of CRPC including chemotherapy, hormonal therapies, antiangiogenetic and immune strategies.

Original languageEnglish
Pages (from-to)1004-1008
Number of pages5
JournalCancer Biology and Therapy
Issue number11
Publication statusPublished - Sep 2012


  • Abiraterone acetate
  • Antiangiogenic therapy
  • Cabazitaxel
  • Chemotherapy
  • CRPC
  • Hormone therapy
  • MDV3100
  • Second-line therapy
  • Sipuleucel-T
  • TAK 700

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant'. Together they form a unique fingerprint.

Cite this